

## Special Issue

# Antiviral Drug Combinations

### Message from the Guest Editor

Viral diseases are the leading cause of morbidity and mortality in developing countries. Antiviral agents are key players in the control of viral diseases. Antiviral agents could be combined to obtain synergistic or additive effects against certain viruses. Combination therapies became a standard for the treatment of HIV and HCV infections. These include abacavir/dolutegravir/lamivudine (Triumeq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza), lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir. Drug combinations could also be used to target several viral infections or co/infections. Such combinations could serve as frontline therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant viral strains. We thus invite submission of original research manuscripts and review articles that cover any aspects of antiviral drug combinations and related topics. I look forward for your contribution.

### Guest Editor

Prof. Dr. Denis E. Kainov

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7028 Trondheim, Norway

### Deadline for manuscript submissions

closed (31 August 2020)



## Viruses

an Open Access Journal  
by MDPI

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/35035](https://mdpi.com/si/35035)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).